New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles

Journal of Immunotherapy

Volumn 30, Issue 3, 2007, Pages 274-281

  Matsueda, Satoko ^a   Takedatsu, Hiroko ^a   Sasada, Tetsuro ^c   Azuma, Koichi ^a   Ishihara, Yuki ^a   Komohara, Yoshihiro ^a   Noguchi, Masanori ^b   Shichijo, Shigeki ^a   Itoh, Kyogo ^a   Harada, Mamoru ^a,b,d  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Kitano Hospital   (Japan)

^d SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

A3 supertype; CTLs; Epithelial cancer; Peptide; Vaccine

Indexed keywords

ALANYLPROLYLALANYLGLYCYLARGINYLPROLYLSERYLALANYLSERYLARGININE; ALANYLVALYLPHENYLALANYLASPARTYLARGINYLLYSYLSERYLASPARTYLALANYLLYSINE; ARGINYLSERYLARGINYLARGINYLVALYLLEUCYLTYROSYLPROLYLARGININE; ASPARAGINYLVALYLLYSYLASPARAGINYLLEUCYLTYROSYLGLUTAMYLLYSYLVALYLLYSINE; CANCER VACCINE; HISTIDYLMETHIONYLPHENYLALANYLASPARTYLVALYLTHREONYLSERYLARGININE; HISTIDYLPROLYLLEUCYLVALYLPHENYLALANYLHISTIDYLTHREONYLASPARAGINYLARGININE; HLA A1 ANTIGEN; HLA A3 ANTIGEN; IMMEDIATE EARLY PROTEIN; LEUCYLLEUCYLGLYCYLPROLYLGLYCYLARGINYLGLYCYLARGINYLPROLYLTYROSYLARGININE; PEPTIDE; RAN PROTEIN; UNCLASSIFIED DRUG; VALYLLEUCYLTYROSYLPROLYLARGINYLVALYLVALYLARGINYLARGININE;

ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DETERMINATION; DRUG EFFECT; DRUG SPECIFICITY; ETHNIC GROUP; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN MOTIF;

ALLELES; ANTIBODIES, BLOCKING; APOPTOSIS REGULATORY PROTEINS; CANCER VACCINES; CARCINOMA; EPITHELIAL CELLS; HLA-A ANTIGENS; HLA-A3 ANTIGEN; HUMANS; MEMBRANE PROTEINS; PEPTIDE FRAGMENTS; RAN GTP-BINDING PROTEIN; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

EID: 34247156114     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211340.88835.e7     Document Type: Article

References (21)

1. Renkvist N, Castelli C, Robbins PF, et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 2001;50:3-15.
2. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics. 1999;50:201-212.
3. Wang RF, Johnston SL, Southwood S, et al. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol. 1998;160:890-897.
4. Missale G, Redeker A, Person J, et al. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med. 1993;177:751-762.
5. + cancer patients. Clin Cancer Res. 2004;10:1112-1120.
6. Matsueda S, Takedatsu H, Yao A, et al. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res. 2005;11:6933-6943.
7. Sasada T, Tadedatsu H, Azuma K, et al. Immediate early response gene X-1, a stress-inducible anti-apoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of induing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients. Cancer Res. 2004;64:2882-2888.
8. Azuma K, Sasada T, Tadedatsu H, et al. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients. Clin Cancer Res. 2004;10:6695-6702.
9. Schaffer H, Trauzold A, Siegel EG, et al. PRG1: a novel early-response gene transcriptionally induced by pituitary adenylate cyclase activating polypeptide in a pancreatic carcinoma cell line. Cancer Res. 1996;56:2641-2648.
10. Pietzsch A, Buchler C, Aslamidis C, et al. Identification and characterization of a novel monocyte/macrophage differentiation-dependent gene that is responsive to lipopolysaccharide ceramide, and lysophosphatidylcholine. Biochem Biophys Res Commun. 1997;235:4-9.
11. Wu MX. Roles of the stress-induced gene IEX-1 in reluation of cell death and oncogenesis. Apoptosis. 2003;8:11-18.
12. Weis K. Regulating access to the genome: nucleocytoplasmic transport throughout the cell cycle. Cell. 2003;112:441-451.
13. Kunzler M, Hurt E. Targeting of Ran: variation on a common theme? J Cell Sci. 2001;114:3233-3241.
14. Aizawa M. The Proceedings of the 3rd Asia-Oceania Histocompatibility Workshop Conference. Oxford: Oxford University Press; 1986: 1090-1103.
15. Hida N, Maeda Y, Katagiri K, et al. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother. 2002;51:219-228.
16. Rammensee HG, Friege T, Stevanovic S. MHC ligands and peptides motifs. Immunogenetics. 1995;41:178-228.
17. Sidney J, Grey HM, Southwood S, et al. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol. 1996;45:79-93.
18. Parker KC, Bednarek MA, Cokigan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163-175.
19. Sato Y, Shomura H, Maeda Y, et al. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci. 2003;94:802-808.
20. Mine T, Gouhara R, Hida N, et al. Immunological evaluation of CTL precursors-oriented vaccines for advanced lung cancer patients. Cancer Sci. 2003;94:548-556.
21. Mine T, Sato Y, Noguchi M, et al. Humoral responses to peptides correlated with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res. 2004;10:929-937.